ROCKVILLE, Md., April 17, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical data for its clinical-stage product candidate, ENMD-1198. The data were presented by EntreMed scientists and collaborators during two separate sessions at the American Association for Cancer Research (AACR) Annual Meeting being held this week in Los Angeles, California.
ENMD-1198, a new chemical entity (NCE) based on a modified chemical structure of 2-methoxyestradiol (2ME2), is designed to decrease metabolism while retaining 2ME2's multiple mechanisms of action, including inducing apoptosis, disrupting microtubules, and inhibiting HIF-1 alpha. In preclinical studies, ENMD-1198 has been shown to be an orally active, antimitotic agent that leads to arrest of cell division and apoptosis in tumor cells. ENMD-1198 also exerts antiangiogenic activity that further contributes to its overall antitumor effects.
Results demonstrate that oral administration of ENMD-1198 was well tolerated and produced significant dose-dependent antitumor activity in a preclinical breast tumor model. Histologic staining and evaluation of tumor sections from the breast cancer model demonstrated a decrease in HIF-1 alpha, tumor cell growth (PCNA), and angiogenesis (CD31). HIF-1 alpha is a protein that is upregulated in many human tumors and has been shown to promote tumorigenesis and decrease tumor cell sensitivity to anticancer agents.
In a separate preclinical study, conducted by EntreMed collaborators at the Children's Cancer Institute Australia for Medical Research and the University of New South Wales, ENMD-1198 demonstrated antitumor activity against vinca alkaloid (micro tubule destabilizing agent) sensitive and resistant leukemia cell lines. Results from in vivo studies also showed that treatment with ENMD-1198 prolonged survival rates significantly in vinca alkaloid sensitive and resistant (ALL3, ALL7 and ALL19) preclinical leukemia models.
"These data further support ENMD-1198's potential for broad application in a variety of solid and hematological cancers," said Carolyn F. Sidor, M.D., M.B.A., EntreMed's Vice President and Chief Medical Officer. "Preclinical studies with ENMD-1198 continue to highlight its significant antitumor activity and multiple mechanisms of action. These studies will help guide our selection of indications for further clinical development. ENMD-1198 is currently in a Phase 1 dose-escalation study in advanced cancer patients, and we anticipate presentation of interim clinical data from the Phase 1 study later this year."
To view the poster presentations, visit Scientific Presentations under the Therapeutic Pathways section of the Company's web site at http://www.entremed.com.
EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell cycle regulator, is in Phase 2 studies for cancer. ENMD-1198, a novel tubulin binding agent, is also in Phase 1 studies in advanced cancers. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's website at http://www.entremed.com and in various filings with the Securities and Exchange Commission.
Forward Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the integration of Miikana and its product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
CONTACT: Ginny Dunn Associate Director, Corporate Communications & Investor Relations EntreMed, Inc. 240-864-2643
CONTACT: Ginny Dunn, Associate Director, Corporate Communications &Investor Relations of EntreMed, Inc., +1-240-864-2643
Web site: http://www.en tremed.com/
Ticker Symbol: (NASDAQ-NMS:ENMD)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company